NCT03245229

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Idorsia Pharmaceuticals Ltd. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The primary purpose of this study is to investigate the effect of Aprocitentan (ACT-132577) at steady state on the pharmacokinetics of single-dose rosuvastatin in healthy male subjects

Conditions

• Healthy Subjects

Interventions

Type	Name	Description
DRUG	Aprocitentan	Capsule for oral administration
DRUG	Rosuvastatin	Tablet for oral administration

Timeline

• Start date: 2017-08-10
• Primary completion: 2017-09-18
• Completion: 2017-09-18
• First posted: 2017-08-10
• Last updated: 2022-11-29

Locations

1 site across 1 country: Czechia